Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.53 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.53 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.40 |
| ▸ | CBFB | Q13951 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9863411 | 0.85 | MAPKAPK2 (0.56) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL29965007 | 0.85 | RPS6KA3 (0.47) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL23977871 | 0.85 | RPS6KA3 (0.47) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL29338767 | 0.81 | MAPKAPK2 (0.44) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL30806374 | 0.80 | ALDH1A1 (0.56) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL706811 | 0.77 | MAPKAPK2 (0.64) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL706055 | 0.77 | MAPKAPK2 (0.50) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL31214307 | 0.76 | RPS6KA3 (0.53) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL2947345 | 0.76 | MAPKAPK2 (0.53) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL2948093 | 0.76 | MAPKAPK2 (0.53) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024170772-A1 | EPIGALLOCATECHIN-3-GALLATE (EGCG) ANALOGS FOR USE IN THE TREATMENT OF DISEASES IN WHICH AN INCREASE OF NAD+ IS BENEFICIAL SUCH AS GLAUCOMA | MIM NEUROSCIENCES AB (SE) | 2024-08-22 | — | — | WO | claimed |
| WO-2024170772-A1 | EPIGALLOCATECHIN-3-GALLATE (EGCG) ANALOGS FOR USE IN THE TREATMENT OF DISEASES IN WHICH AN INCREASE OF NAD+ IS BENEFICIAL SUCH AS GLAUCOMA | MIM NEUROSCIENCES AB (SE) | 2024-08-22 | — | — | WO | disclosed |
| CN-109121397-A | Heterocyclic compound, especially 2- oxo -4,4,5,5,6,6,7,7- octahydro benzoxazoles derivatives and their purposes as antimicrobial compound | 莱德克斯制药公共有限公司 | 2019-01-01 | — | — | CN | disclosed |
| US-9936700-B2 | Substituted quinoxaline derivatives as pest control agent | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-04-10 | — | — | US | disclosed |
| US-9936700-B2 | Substituted quinoxaline derivatives as pest control agent | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-04-10 | — | — | US | disclosed |
| US-9936700-B2 | Substituted quinoxaline derivatives as pest control agent | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-04-10 | — | — | US | disclosed |
| EP-3060557-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AS PEST CONTROL AGENT | Bayer CropScience Aktiengesellschaft (DE) | 2016-08-31 | — | — | EP | disclosed |
| CN-105873914-A | Substituted quinoxaline derivatives as pest control agents | 拜耳作物科学股份公司 | 2016-08-17 | — | — | CN | disclosed |
| US-20160227779-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AS PEST CONTROL AGENT | BRETSCHNEIDER, NIKLAS TIM (DE) | 2016-08-11 | — | — | US | disclosed |
| US-20160227779-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AS PEST CONTROL AGENT | BRETSCHNEIDER, NIKLAS TIM (DE) | 2016-08-11 | — | — | US | disclosed |
| WO-2008009700-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
| WO-2006134378-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | WO | disclosed |
| EP-0518530-B1 | Improvements in or relating to excitatory amino acid receptor antagonists | LILLY CO ELI (US) | 1996-10-09 | — | — | EP | disclosed |
| EP-0520024-B1 | QUINOXALINE COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 1996-06-19 | — | — | EP | disclosed |
| US-5196421-A | Treatment of neurological disorders | ELI LILLY AND COMPANY (US) | 1993-03-23 | — | — | US | disclosed |
| EP-0520024-A1 | QUINOXALINE COMPOUNDS AND THEIR PREPARATION AND USE. | NOVO NORDISK AS (DK) | 1992-12-30 | — | — | EP | disclosed |
| EP-0518530-A2 | Improvements in or relating to excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1992-12-16 | — | — | EP | disclosed |
| US-5166155-A | Neurological or psychiatric diseases | NOVO NORDISK A/S (DK) | 1992-11-24 | — | — | US | disclosed |
| US-5153196-A | Administering for reduction of neurotransmission in nervous system disorders | ELI LILLY AND COMPANY (US) | 1992-10-06 | — | — | US | disclosed |
| WO-1991013878-A1 | QUINOXALINE COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1991-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160227779-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AS PEST CONTROL AGENT | CHRM1, CHRM2, ACHE | MAPKAPK2 3424/4885RPS6KA3 648/4885CSNK2A1 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.